PONT-DU-CHÂTEAU, France, Aug. 16, 2023 /PRNewswire/ — Dômes Pharma reveals that it has actually settled the acquisition of SentrX Animal Care, a US business based in Salt Lake City (Utah). SentrX establishes and makes ophthalmology items based upon its special BioHAnce™ innovation. BioHAnce™ is a trademarked crosslinked Hyaluronic Acid innovation that boosts and speeds up natural recovery, hydration and lubrication procedures, while minimizing the variety of applications. The business, which has its own 2,000 m2 factory, markets 3 items that have actually quickly acquired market share in the United States and Europe, significantly in the UK, thanks to their efficiency and ease of usage.
Less than a year after the opening of its subsidiary in Boston (Massachusetts), this acquisition marks a crucial action in Dômes Pharma’s aspirations in North America and verifies its positioning in veterinary ophthalmology. In France, the Auvergne-based independent group owns the TVM brand name, a leader in this healing field for almost 40 years and a professional in the management and treatment of poisoning and epilepsy. Since 2015 the Group has actually carried out global growth with the opening of subsidiaries in England, Germany, Spain and most just recently the U.S.A. along with a network of suppliers in Europe.
Geographical, commercial and healing synergies
For Anne Moulin, President of Dômes Pharma United States and the 3rd generation to establish the family business, this acquisition is the conclusion of the internationalization technique she has actually instilled in the Group, and her choice to end up being personally associated with the North American experience by transferring to Boston in September 2022:
« We are pleased to have actually settled the acquisition of Sentrx Animal Care in such a brief space of time. The geographical, commercial and healing synergies in between our 2 business are so apparent that we were produced each other. For both Sentrx and us, this acquisition comes at the correct time, and will allow us to continue to assert our competence in ophthalmology in Europe, and to develop ourselves in North America in among the Group’s locations of quality. It’s a wonderful chance for us to broaden more quickly in the United States, while waiting for the upcoming FDA registration of our items.
For Sentrx, it’s a chance to pursue its advancement, especially in Europe, by signing up with a human-scale group with the exact same vertical combination and competence in animal health. Sentrx items are extremely complementary to our ophthalmology variety, and their BioHAnceTM innovation platform opens appealing brand-new advancements for our existing items. ».
Anne Moulin, who takes control of the management of Sentrx, will have the ability to depend on the assistance of Brian Segebrecht, the previous President and CEO, who was likewise persuaded of the best complementarity of the 2 entities:
« The Domes Pharma organization has an outstanding enduring performance history of quality in bringing items to market that enhance the lives of animals and those who look after them. However, throughout this sale procedure I have actually been most satisfied by a shared set of worths and goals in between the 2 business, especially in the field of veterinary ophthalmology. As an outcome of this deal more pet owners and vets in more markets will have access to a better offering of ingenious ophthalmology services, eventually enhancing the lives of more animals around the globe, which is interesting. Anne Moulin has a remarkable vision for speeding up access to our ingenious BioHAnce™ innovation, along with other ingenious animal health services, and I actually anticipate supporting her as she builds on the structure the SentrX group has actually worked to develop over the last 5 years. »
BioHAnce™, an unique HA innovation
Sentrx’s special, trademarked BioHAnce innovation develops a macromolecular matrix of hyaluronic acid through an ingenious cross-linking response. This innovation likewise permits control of the cross-linking rate, which can be adjusted to the targeted tissues, and ensures an incomparable degree of pureness, improving biocompatibility. This initial matrix can be utilized to boost the moisturizing and protective homes of services including it. Cross-connected hyaluronic acid likewise speeds up the recovery procedure by producing an anchoring assistance for restoration consider harmed tissue. At comparable concentrations, BioHance hyaluronic acid is more thick than traditional hyaluronic acid and has exceptional muco-adhesive homes, allowing it to stay on the eye for longer, thus offering much better hydration and a much better environment for tissue recovery.
Already an essential in the UK, Sentrx items are not presently dispersed in France. They will soon be provided by Dômes Pharma France.
About Dômes Pharma Group
The independent family group Dômes Pharma has actually existed in the pharmaceutical market given that 1947 and count 400 workers at 7 websites, with a combined turnover of €87 million (2022). Since 2015 the Group has actually carried out global growth with the opening of subsidiaries in England, Germany, Spain and most just recently the U.S.A. along with a network of suppliers in Europe.
For over 70 years, the Group has actually been establishing, producing and marketing services for the health and wellness of buddy animals. Through its subsidiaries, the Dômes Pharma Group boasts 3 complementary locations of competence, covering the whole worth chain and covering all circulation channels. Leaders in ophthalmology, poisoning management and epilepsy, our items fulfill genuine requirements and typically fill healing spaces. Fully dedicated to enhancing access to veterinary medication, we bring appropriate enhancements and development to vets and animal owners in our locations of competence.
Because human beings, animals and the environment are connected by nature, looking after the animals that share our every day lives suggests maintaining the health of all. This conviction is revealed in our slogan “CONNECTED BY NATURE” influenced by the idea of “One Health”.
About Sentrx Animal Care, Inc.
Founded in 2006 from a trademarked innovation established with the University of Utah, Sentrx is a Salt Lake City-based animal health business that establishes and makes veterinary items for ophthalmology and injury care. Sentrx changes intricate biotechnologies into user friendly care services that promote the long-lasting wellness of animals. The special, trademarked BioHAnce™ innovation utilizes sophisticated bioengineering to produce a cross-linked hyaluronic acid (HA) molecular matrix that can be particularly customized for each specific solution and tissue environment, consisting of ocular and skin surface areas. It produces a cellular matrix with distinct physical and chemical homes that boosts hydration, speeds up the body’s own recovery procedures and extends duration in tissue.
Sentrx teams up with a range of veterinary scholastic organizations and practicing vets. Its distinct mix of medical chemistry, bioengineering and item production abilities allows it to supply innovative services for animal care.
SentrX was recommended by the Animal Health Group at Corporate Finance Associates, an independent financial investment banking company, on the deal.
View initial material to download multimedia:
SOURCE Sentrx Animal Care; Dômes Pharma Group
